NEXGEL, Inc. (NXGL)
NASDAQ: NXGL · IEX Real-Time Price · USD
2.365
+0.145 (6.53%)
At close: May 17, 2024, 4:00 PM
2.430
+0.065 (2.75%)
After-hours: May 17, 2024, 4:52 PM EDT
NEXGEL Revenue
NEXGEL had revenue of $4.74M in the twelve months ending March 31, 2024, with 108.36% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.27M with 104.19% year-over-year growth. In the year 2023, NEXGEL had annual revenue of $4.09M with 99.66% growth.
Revenue (ttm)
$4.74M
Revenue Growth
+108.36%
P/S Ratio
3.12
Revenue / Employee
$249,263
Employees
19
Market Cap
14.79M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4.09M | 2.04M | 99.66% |
| Dec 31, 2022 | 2.05M | 497.00K | 32.04% |
| Dec 31, 2021 | 1.55M | 877.00K | 130.12% |
| Dec 31, 2020 | 674.00K | -43.00K | -6.00% |
| Dec 31, 2019 | 717.00K | -1.50M | -67.60% |
| Dec 31, 2018 | 2.21M | 221.00K | 11.09% |
| Dec 31, 2017 | 1.99M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Star Equity Holdings | 45.79M |
| Pieris Pharmaceuticals | 40.93M |
| Psychemedics | 21.60M |
| Immuron | 2.43M |
| Akso Health Group | 2.20M |
| Addex Therapeutics | 1.96M |
| Mainz Biomed B.V. | 895.48K |
NXGL News
- 2 days ago - NEXGEL Acquires International Beauty Brand, Silly George - GlobeNewsWire
- 6 weeks ago - NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year - GlobeNewsWire
- 7 weeks ago - NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday - GlobeNewsWire
- 2 months ago - NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th - GlobeNewsWire
- 2 months ago - NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th - GlobeNewsWire
- 4 months ago - NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024 - GlobeNewsWire
- 5 months ago - NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America - GlobeNewsWire
- 6 months ago - NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year - GlobeNewsWire